Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

354
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
354
Cross-bridge Cycle01:26

Cross-bridge Cycle

121.9K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
121.9K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.6K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.6K
Muscles that Move the Arm01:31

Muscles that Move the Arm

4.5K
Nine muscles are involved in arm movements. Two of these, the pectoralis major and latissimus dorsi, originate from the axial skeleton and are called axial muscles. The other seven originate from the scapula and are called the scapular muscles.
The pectoralis major has two origins. Its clavicular head originates on the medial half of the clavicle. In contrast, the sternocostal head originates on the costal cartilages of ribs 1-6, the sternum, and the aponeurosis of the external oblique of the...
4.5K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-Translational Modifications of the DUX4 Protein Impact Toxic Function in FSHD Cell Models.

Annals of neurology·2023
Same author

Hypoxic preconditioning protection is eliminated in HIF-1α knockout mice subjected to neonatal hypoxia-ischemia.

Pediatric research·2014
See all related articles

Related Experiment Video

Updated: Jan 6, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.0K

Facioscapulohumeral Muscular Dystrophy.

Renatta N Knox

    Continuum (Minneapolis, Minn.)
    |October 2, 2025
    PubMed
    Summary

    Facioscapulohumeral muscular dystrophy (FSHD) is caused by toxic DUX4 gene expression, leading to progressive muscle weakness. New therapies targeting DUX4 are advancing, offering hope for disease-modifying treatments.

    Area of Science:

    • Genetics and Molecular Biology
    • Neurology
    • Clinical Therapeutics

    Background:

    • Facioscapulohumeral muscular dystrophy (FSHD) is a common, progressive neuromuscular disorder with variable severity.
    • It is characterized by muscle weakness affecting the face, shoulders, and limbs, and can include extramuscular symptoms.
    • Pediatric-onset FSHD may present with more severe features, including hearing loss and cognitive issues.

    Purpose of the Study:

    • To provide a comprehensive overview of FSHD, covering its genetic basis, clinical presentation, and current/emerging treatments.
    • To highlight the role of DUX4 gene misexpression in FSHD pathogenesis.
    • To discuss the evolving landscape of clinical trials for disease-modifying therapies.

    Main Methods:

    • Review of genetic mechanisms underlying FSHD.

    More Related Videos

    Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
    07:48

    Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

    Published on: September 16, 2019

    10.4K
    Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
    10:28

    Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

    Published on: April 3, 2021

    7.0K

    Related Experiment Videos

    Last Updated: Jan 6, 2026

    Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
    08:16

    Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

    Published on: March 4, 2014

    33.0K
    Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
    07:48

    Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

    Published on: September 16, 2019

    10.4K
    Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
    10:28

    Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

    Published on: April 3, 2021

    7.0K
  • Analysis of clinical manifestations, including pediatric-specific features.
  • Examination of current and future therapeutic strategies and clinical trials.

    • Main Results:

    • FSHD results from toxic DUX4 transcription factor derepression, impacting skeletal muscle.
    • Progressive muscle weakness, often asymmetric, and extramuscular symptoms are key features.
    • Advances in understanding DUX4 have spurred the development of targeted therapies and clinical trials.

    Conclusions:

    • FSHD is driven by toxic DUX4 expression, leading to characteristic muscle weakness and potential extramuscular issues.
    • The field is moving towards targeted, disease-modifying treatments for FSHD.
    • Clinical trials are underway, signaling a new era of therapeutic development for FSHD patients.